YieldMax AMD Option Income Strategy ETF vs Cytokinetics Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.86, while Cytokinetics Inc trades at $76.62 (market cap $10.63B). The key difference: Cytokinetics Inc is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | CYTK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.52 | $87.26 |
52-Week Low | $29.80 | $34.31 |
Market Cap | — | $10.63B |
Enterprise Value | — | $10.74B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Trailing returns across standard periods
Latest headlines on both assets
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →